"Education is not the learning of facts, but the training of the mind to think." - A. Einstein "Education is not the learning of facts, but the training of the mind to think." - Malcolm X Education is knowing what to do when you dont know what to do https://t.co/5CF4g78OEH

Secukinumab fails in GCA phase 3 RCT. Novartis announced top-line results from the GCAptAIN study evaluating secukinumab in adults with newly diagnosed or relapsing GCA. In a steroid taper RCT, the endpoint was sustained remission at Wk 52 compared to placebo https://t.co/JuMDPvznCn

Case series of 22 PsA pts treats w/ combination bioDMARDs & JAKi,TYK2i or APR IL17i + JAKi 10.5 PY = 1 mild infectious stomatitis IL23i + JAKi 3.7 PY = no AE IL-17i + TYK2i 8.5 PY = 2 mild upper respiratory infections IL-23i + TYK2i 8.3 PY = 2 mild URIs, 1 folliculitis TNFi + https://t.co/hxhTxmJpbN

First FcRn inhibitor in #IIM: In #ALKIVIA, SC efgartigimod PH20 improved TIS vs placebo at 24wks (50.45 vs 35.65, p=0.0004), with faster time to TIS≥20 (30 vs 71.5d) & TIS≥40 (113d vs NE). More major responders too (TIS>60: 34% vs 9.5%). #EULAR2025 #OP0002 https://t.co/ulxtL1NX2Y

In >228k CTD patients across France, ILD increased mortality risk across all CTDs. Proportion of incident CTD with ILD highest in IIM (37%). Up to 34% of CTD-ILD pts had progressive pulm fibrosis. Supports earlier ILD screening & vigilance in CTDs. @RheumNow #EULAR2025 #OP0033 https://t.co/nEiTWQEqsP

If you successfully taper off DMARDs in RA patients in remission, do you risk bringing new joints in the mix? Leiden post-hoc trial: these patients don’t do worse than those who never get off drug. Drug-free remission tricky but new joints not a worry. #EULAR2025 @RheumNow https://t.co/bwXgrB875k

Clinical determinants of multiple drug failure in D2T RA 2000+ RA cohort 250+ refractory -Low financial status -Cancer Hx -CV comorbidities -Chronic use of NSAID or GCs Protective: Regular participation in leisure activities #POS0030 @RheumNow #EULAR2025 https://t.co/mdePGkHU82

ICYMI: Introducing Polyrefractory RA: A New Frontier in Difficult-to-Treat RA At a EULAR 2025 session titled “What makes ‘Difficult-to-treat RA’ so difficult to treat? And what can we do?”, Drs. Paula David and Dennis McGonagle introduced the emerging concept of polyrefractory https://t.co/Qy9fy3GWKm

POCUS of the lung can detect subclinical ILD and can be a useful, inexpensive, easy to perform screening tool for CTD-ILD. #EULAR2025 @RheumNow https://t.co/HC0skwUKQG

Foot and ankle #OA is often underrecognized.. 1 in 6 people over 50 have foot OA! #EULAR2025 @RheumNow https://t.co/4wGSzC8dvi

How to patients with rheumatic diseases consume online health information? 78% used internet for health information 50% use it atleast a month 66% found online information superior 41% used social media! 80% using it to find treatment optio ns! @rheumnow #EULAR2025 https://t.co/ZcjwPaqsjT

FDA approves new drug for MAS in Still's disease. Gamifant (emapalumab-lzsg) is interferon gamma (IFNγ)–blocking Ab approved For HLH, now for use in adults & children w/ Still's Dz complicated by Macrophage Activation Syndrome. https://t.co/3div1fktWU https://t.co/VvSkuEoki5